Hey fellas, I hate to tell you, but unless you are a wickedly careful momentum player, you have thwe potential to get killed on the short side with this stock. It has a market cap of less than $150 million, and a drug completing trials this year with a potential for annual sales of well over a billion per year. The next year or two will be littered with very frequent reports from the trials which are bound to propel the stock. Centocor had some down periods on the way from $7 to $42, but would you have been safe short the stock at any period (I have been long CNTO the whole way).
Hey Rudy, nice to see you back. I take special pleasure in needling you. When I correctly predicted several months ago, when the stock was at $3, that a deal would be signed, and the stock would be over $6 by year end you ridiculed me. Well I was right on all counts, and you were quite wrong. This stuff is fun isn't it? |
